Detail of "112362-50-2"

Reference

Pharmacology and pharmacokinetics of the streptogramin antibiotic quinupristin and dalfopristin

Pharmacology and pharmacokinetics of the streptogramin antibiotic quinupristin and dalfopristin. Saito, Ken; Takasugi, Masumitsu (Aventis Pharma Ltd., Japan). Kagaku Ryoho no Ryoiki, 18(6), 873-883 (Japanese) 2002 Iyaku Janarusha. CODEN: KRRYEI. ISSN: 0913-2384. 112362-50-2 and 120138-50-3 are cas registry numbers of chemicals which are used as reagents here. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review, discussing the chem., antimicrobial pharmacol. and pharmacokinetics of the streptogramin antibiotics quinupristin and dalfopristin. .

Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristindal): a report of fifteen cases

Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristindal): a report of fifteen cases. Dever, Lisa L.; Smith, Sharon M.; Dejesus, Dino; Masurekar, Malthi; Patel, Deepa; Kaminski, Zigmund C.; Johanson, W. G., Jr. (Infectious Diseases Section, Medical Service, Dep. of Veterans Affairs Medical Center, East Orange, NJ 07018, USA). Microbial Drug Resistance (Larchmont, New York), 2(4), 407-413 (English) 1996 Liebert. CODEN: MDREFJ. ISSN: 1076-6294.There are some reagents with their cas registry numbers 120138-50-3 and 112362-50-2 are used in this study. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) New therapies for vancomycin-resistant Enterococcus faecium (VREF) infections are urgently needed. We describe the treatment of 15 patients with VREF infection with quinupristin/dalfopristin (RP 59500), a new injectable streptogramin antibiotic. Primary infections treated were bacteremia (4), urinary tract (4), intraabdominal (5), otitis externa (1), and meningitis (1). Min. inhibitory concns. for quinupristin/dalfopristin ranged from 0.5 mg/mL or less to 2 mg/mL, and min. bactericidal concns. were greater than 64 mg/mL for all VREF isolates tested. Peak serum inhibitory titers following infusion of quinupristin/dalfopristin ranged from 1:8 to 1:64, all bactericidal titers were less than 1:2. Development of resistance to quinupristin/dalfopristin during therapy was not obsd. The only drug-related adverse effect noted was phlebitis in 4 patients; all had received quinupristin/dallfopristin by peripheral venous infusion. Three patients had clin. and bacteriol. cures. Relapses occurred in 5 patients with recovery of VREF from infected sites in post-treatment cultures. Ten patients died of severe underlying disease; VREF was believed to contribute directly to the death of only 1 patient. While evaluation of clin. efficacy was complicated by the severity of underlying disease in patients with VREF infection, our experience suggests that quinupristin/dalfopristin is a safe and potentially useful agent for the treatment of VREF infections. .